Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Acquisitions & Divestments (2016 - 2026)

Corvus Pharmaceuticals' Change in Acquisitions & Divestments history spans 12 years, with the latest figure at $17.0 million for Q1 2026.

  • Quarterly Change in Acquisitions & Divestments rose 41.67% to $17.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $89.1 million through Mar 2026, up 78.26% year-over-year, with the annual reading at $84.1 million for FY2025, 97.34% up from the prior year.
  • Change in Acquisitions & Divestments came in at $17.0 million for Q1 2026, down from $24.3 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $28.5 million in Q3 2025 to a low of $810000.0 in Q1 2022.
  • The 5-year median for Change in Acquisitions & Divestments is $15.4 million (2022), against an average of $14.7 million.
  • Year-over-year, Change in Acquisitions & Divestments crashed 90.08% in 2022 and then surged 2088.27% in 2023.
  • Corvus Pharmaceuticals' Change in Acquisitions & Divestments stood at $15.4 million in 2022, then plummeted by 40.85% to $9.1 million in 2023, then soared by 56.73% to $14.3 million in 2024, then surged by 70.41% to $24.3 million in 2025, then plummeted by 30.18% to $17.0 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Change in Acquisitions & Divestments are $17.0 million (Q1 2026), $24.3 million (Q4 2025), and $28.5 million (Q3 2025).